[Cost effectiveness of pravastatin in secondary coronary prevention in patients with myocardial infarct or unstable angina in Germany. An analysis on the basis of the LIPID trial]

Herz. 2000 Aug;25(5):487-94. doi: 10.1007/pl00001961.
[Article in German]


Secondary coronary prevention with lipid lowering drugs has become a major issue in health policy formulation due to the large upfront investment in drug therapy. The recently completed LIPID trial with pravastatin in secondary prevention immediately raise the question whether pravastatin might be cost-effective in Germany. We conducted a cost-effectiveness analysis from the perspective of third party payers. The following costs were included in the analysis: daily treatment costs of pravastatin, non-fatal myocardial infarction, coronary bypass operations and stroke. Life years gained were obtained by applying the declining exponential approximation of life expectancy. All calculations were standardized to 1,000 treated patients. The net costs of treating 1,000 patients (i.e. drug costs minus the costs of sequelae and interventions) are DM 8.4 Mio. In addition, a total of 405 life years may be saved through treatment. The corresponding cost-effectiveness of pravastatin treatment is DM 20,674,-(DM 17,314,-, discounted by 3% p.a.).

Publication types

  • Comparative Study
  • English Abstract

MeSH terms

  • Angina, Unstable / drug therapy*
  • Angina, Unstable / economics
  • Anticholesteremic Agents / economics*
  • Anticholesteremic Agents / therapeutic use
  • Clinical Trials as Topic
  • Coronary Disease / economics
  • Coronary Disease / prevention & control*
  • Cost-Benefit Analysis
  • Costs and Cost Analysis
  • Female
  • Germany
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / economics*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Life Expectancy
  • Male
  • Middle Aged
  • Myocardial Infarction / drug therapy*
  • Myocardial Infarction / economics
  • Pravastatin / economics*
  • Pravastatin / therapeutic use
  • Quality of Life


  • Anticholesteremic Agents
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Pravastatin